ddPCR to Determine the Expression and Potency of AAV Vectors

Introduction

Adeno-associated virus (AAV) vectors have emerged as the leading platform for gene therapy due to their favorable safety profile and ability to efficiently transduce diverse cell types. As AAV-based therapeutics advance through clinical development, establishing robust analytical methods to assess vector potency is critical for ensuring product quality, manufacturing consistency, and patient safety.

Potency testing for AAV vectors presents unique challenges. Unlike small molecule drugs or biologics where activity can be directly measured through biochemical assays, AAV potency must capture the vector’s ability to deliver and express a functional transgene in target cells. Traditional protein-based potency assays, such as Western blotting or ELISA, often require extensive development, are challenging to optimize, and can be time-consuming to perform. These limitations have driven the field toward molecular methods that offer superior quantitative accuracy and reproducibility.

Droplet digital PCR (ddPCR) has emerged as a powerful alternative for AAV potency assessment. By enabling precise quantification of transgene mRNA expression in transduced cells, ddPCR provides a direct molecular readout that correlates vector genome input with biological activity. This blog outlines a systematic strategy for developing fit-for-purpose ddPCR-based potency assays tailored to AAV vectors, with emphasis on scientific rationale, technical optimization, regulatory alignment, and phase-appropriate implementation across the product lifecycle—from early research through GMP clinical manufacturing.

Why ddPCR for AAV- Based Gene Therapy Products?

The ddPCR technology offers several distinct advantages over conventional quantitative PCR (qPCR) and other analytical platforms that make it particularly well-suited for AAV potency testing:

Absolute Quantification: ddPCR partitions each reaction into thousands of nanoliter-scale droplets, enabling direct counting of target nucleic acid molecules without reliance on standard curves. This eliminates quantification bias introduced by variable amplification efficiency.

Superior Precision: The digital nature of ddPCR provides exceptional accuracy at low copy numbers, with coefficients of variation typically below 10% even at the limits of detection—a critical advantage when measuring transgene expression from limited vector doses.

Robustness to Inhibitors: Unlike qPCR, which relies on cycle threshold (Ct) values that can shift in the presence of PCR inhibitors, ddPCR’s endpoint fluorescence measurement demonstrates remarkable tolerance to matrix effects and sample impurities commonly encountered in biological samples.

Dynamic Range: ddPCR maintains linearity across five to six orders of magnitude, accommodating the wide range of transgene expression levels observed across different multiplicities of infection (MOIs) without sample dilution or re-runs.

Multiplexing Capability: Duplex ddPCR formats enable simultaneous quantification of transgene mRNA and reference housekeeping genes, providing built-in normalization to control for cell number variability and RNA quality differences.

These technical capabilities translate directly to improved assay performance: enhanced sensitivity for detecting low-level transgene expression, greater reproducibility across manufacturing lots, and robust data quality that supports regulatory decision-making throughout clinical development.

ddPCR Methodologies and Their Applications in AAV-Mediated Gene Therapies

Several ddPCR methods are employed to support AAV vector characterization, potency assessment, stability evaluation, lot release testing, pharmacokinetic (PK) studies, and commercialization, each providing distinct analytical advantages.

The RT-ddPCR quantifies transgene mRNA in transduced cells or tissues and can be performed as a two-step or one-step assay. The two-step format separates reverse transcription and amplification, while the one-step version combines both within a single droplet reaction, reducing variability and handling errors.

A duplex RT-ddPCR further improves precision by detecting both the transgene and a housekeeping gene in one reaction, enabling internal normalization and consistent expression analysis across samples.

The 2D ddPCR (two-dimensional ddPCR) expands on this by analyzing whether two targets occur within the same droplet. Using dual fluorescence channels, it produces a scatter plot that differentiates droplets containing none, one, or both targets, revealing molecular linkage and genome integrity within AAV genomes. The 2D ddPCR is especially valuable for AAV genome integrity, co-packaging, and dual-region analysis. Results from RT-ddPCR and 2D ddPCR can be correlated with orthogonal potency assays (e.g., ELISA or functional bioassays) to confirm the biological relevance and accuracy of transgene expression, ensuring data robustness and regulatory compliance.

Four-Stage Development Strategy for Phase-Appropriate ddPCR-Based Potency Assays for AAV Vectors

Developing a ddPCR-based potency assay for AAV vectors requires systematic optimization to ensure the method is quantitative, reproducible, and biologically relevant. The following four-stage approach provides a structured framework for assay development:

Stage 1: Feasibility and Cell Line Selection

The foundation of a successful potency assay begins with selecting an appropriate in vitro system that supports efficient AAV transduction and enables accurate quantification of transgene expression.

Cell Line Screening: Evaluate candidate cell lines expressing relevant AAV receptors, such as AAVR (adeno-associated virus receptor), heparan sulfate proteoglycans, or tissue-specific receptors corresponding to the therapeutic target. Primary cells or physiologically relevant cell lines may provide the most biologically meaningful readout but must be balanced against considerations of availability, consistency, and ease of culture.

Transduction Optimization: Test multiple multiplicities of infection (MOIs), expressed as vector genomes per cell (VG/cell), to establish the assay’s dynamic range. Typical MOI ranges span 10³ to 10⁶ VG/cell, though this should be tailored to the specific vector and transgene expression characteristics.

Sample Processing: Following transduction at defined time points (typically 24–72 hours post-infection), extract total RNA using validated protocols that preserve RNA integrity. Reverse transcribe RNA to cDNA using random primers or oligo(dT) to capture polyadenylated transcripts.

Initial ddPCR Analysis: Quantify transgene mRNA using optimized primer-probe sets targeting the transgene sequence. Evaluate different cDNA input amounts to identify the optimal range that produces measurable signal without saturating the ddPCR system (typically 1–50 ng cDNA per reaction).

Success Criteria: A successful feasibility study demonstrates dose-dependent transgene expression across tested MOIs, with clear separation between transduced and mock-transduced control samples, and consistent droplet quality metrics.

Stage 2: Method Optimization

Once feasibility is established, systematic optimization of experimental parameters enhances assay performance and establishes the conditions that will be carried forward into qualification.

MOI Range Refinement: Narrow the MOI range to identify the linear portion of the dose-response curve where transgene expression increases proportionally with vector input. This typically spans 1.5–2 log₁₀ units and defines the assay’s quantitative range.

Transduction Kinetics: Evaluate transgene expression at multiple time points post-transduction (e.g., 24, 48, 72, 96 hours) to identify the optimal harvest time that maximizes signal while maintaining reproducibility. Consider both peak expression and the stability window where expression remains relatively constant.

cDNA Input Optimization: Systematically test cDNA input amounts to balance sensitivity and precision. Too little input increases variability; too much can saturate the ddPCR system or introduce inhibition. The optimal input typically produces 100–10,000 positive droplets per reaction.

Normalization Strategy: Evaluate whether incorporation of a housekeeping gene (e.g., GAPDH, ACTB, HPRT1) for data normalization improves assay precision. Implement duplex ddPCR to simultaneously measure transgene and reference gene expression, calculating potency as a normalized ratio. Assess whether normalization reduces inter-well or inter-plate variability.

Reagent Optimization: Fine-tune primer and probe concentrations, annealing temperatures, and extension times to maximize amplification efficiency and minimize non-specific background. Optimize droplet generation conditions and thermal cycling protocols according to manufacturer recommendations and (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines (for journal publications only).

Acceptance Criteria Development: Define preliminary acceptance criteria for droplet count, amplitude separation, and no-template controls based on optimization data. These criteria form the foundation for subsequent qualification studies.

Stage 3: Performance Characterization

Comprehensive performance characterization demonstrates that the optimized assay meets scientific and regulatory standards for its intended use. This stage evaluates key analytical parameters aligned with ICH Q2(R2) guidelines for analytical validation and ICH Q6B considerations for biological products.

Linearity: Demonstrate that transgene mRNA quantification is directly proportional to cDNA input across the established working range. Generate a dilution series of a characterized reference sample (typically spanning 5–7 points) and evaluate correlation coefficient (r² ≥ 0.95) and residuals.

Precision: Assess assay reproducibility under multiple conditions:

  • Repeatability (intra-assay): Test replicate samples within a single run by a single operator to establish within-run variability (typically CV ≤ 20%)
  • Intermediate precision (inter-assay): Evaluate variability across different days, analysts, instruments, and reagent lots to capture real-world performance conditions (typically CV ≤ 30%)

 
Accuracy: Evaluate measurement accuracy using reference standards with known transgene copy numbers, spike-recovery experiments, or comparison to orthogonal methods such as RNA-seq or qPCR. Recovery should fall within 80–120% of expected values.

Specificity: Confirm that the assay selectively amplifies only the intended transgene target without cross-reactivity to endogenous sequences, related AAV serotypes, or other potential interferents. Test specificity using:

  • Mock-transduced cells (negative control)
  • Cells transduced with unrelated AAV vectors
  • Genomic DNA to confirm primers do not amplify off-target sequences

 
Sensitivity and Range: Define the lower limit of quantification (LLOQ) as the lowest transgene mRNA concentration that can be measured with acceptable precision and accuracy (typically CV ≤ 25%, accuracy 75–125%). Establish the upper limit of quantification (ULOQ) based on ddPCR system saturation limits.

Robustness: Evaluate assay performance under deliberate variations in critical parameters such as cell passage number, transduction time (±4 hours), cDNA storage conditions, and minor deviations in thermocycling conditions to assess assay resilience.

Sample Stability: Assess stability of transduced cells, extracted RNA, and cDNA under relevant storage conditions (e.g., -80°C for RNA, -20°C for cDNA) to establish appropriate sample handling and hold-time limits.

Stage 4: Implementation and Continuous Monitoring

The final stage transitions the qualified assay into routine use for testing manufacturing lots, with ongoing performance monitoring to ensure sustained reliability.

Standard Operating Procedures: Document all optimized methods, acceptance criteria, and data analysis procedures in comprehensive SOPs that enable consistent execution by trained personnel.

System Suitability: Implement run controls, including characterized reference standards and quality control samples at low, medium, and high expression levels, to verify acceptable assay performance before accepting test sample results.

Performance Trending: Continuously monitor precision, accuracy, and control sample recovery across runs to detect performance drift. Establish alert and action limits based on qualification data, triggering investigation when exceeded.

Comparability Assessments: Apply the validated potency assay to evaluate manufacturing consistency across engineering runs, GLP toxicology lots, and GMP clinical material, establishing acceptance ranges that ensure product comparability.

Lifecycle Management: Document any changes to the assay (reagent lots, equipment, or procedure modifications) through formal change control processes. Conduct bridging studies or requalification as needed to demonstrate continued method suitability.

ddPCR Assay Lifecycle: From Fit-For-Purpose to Validation (GMP)

Fit-for-Purpose Assays (IND-Enabling)

These assays are developed to support early-stage process development and vector construct screening, providing an initial assessment of assay performance through parameters such as linearity and reproducibility. At this stage, documentation typically consists of laboratory notebooks and informal reports. Once the foundational assay framework is established, it is refined to become “fit-for-purpose” for preclinical and early clinical applications. Although not yet fully qualified or validated, these assays are designed to satisfy FDA expectations for inclusion in initial IND submissions. Our ddPCR assay development emphasizes reproducibility, accuracy, and robustness, critical attributes that establish a solid foundation for subsequent assay qualification and full GMP validation.

Qualified ddPCR Assays

Qualified ddPCR assays play a pivotal role in supporting GLP toxicology studies, biodistribution and shedding analyses, and preclinical lot characterization for AAV and other gene therapy products. At this stage, assays undergo formal evaluation of analytical performance parameters, such as precision, accuracy, specificity, and range, under controlled conditions. Detailed qualification reports and SOPs are generated to document performance and ensure compliance with regulatory expectations, making these assays suitable for inclusion in the nonclinical sections of IND submissions.

The goal of assay qualification is to refine and verify performance characteristics that establish reliability and consistency across studies. This includes systematic assessment of robustness, linearity, stability (e.g., freeze/thaw tolerance), and other key parameters to define both system suitability and acceptance criteria.

Validated ddPCR Assays (GMP/Clinical)

Validated assays are required for clinical lot release, stability testing, and commercial manufacturing. They undergo comprehensive validation in accordance with ICH Q2(R2) guidelines, covering parameters such as precision, accuracy, specificity, linearity, range, and robustness. Documentation includes full validation reports, GMP-compliant SOPs, and the use of 21 CFR Part 11-compliant electronic data systems. These assays provide the analytical foundation for supporting the Chemistry, Manufacturing, and Controls (CMC) sections of INDs, BLAs, and marketing applications, ensuring regulatory compliance for clinical and commercial use.

Applications of Phase-Appropriate ddPCR Assays

ddPCR-based methods serve multiple critical roles throughout AAV product development and commercialization. The level of validation required depends on the specific application:

AAV biodistribution studies are critical for understanding how vector genomes distribute, localize, and persist in different tissues following administration. They confirm that vector exposure aligns with the intended therapeutic target and help assess potential off-target or unintended tissue effects. After in vivo administration, tissues such as the liver, heart, kidney, spleen, gonads, brain, and injection site are collected at defined intervals. Genomic DNA is then extracted, and ddPCR is used to quantify vector genome copies per cell or per microgram of DNA using primers specific to unique AAV sequences, such as inverted terminal repeats (ITRs) or transgene regions.

These studies play a key regulatory role by informing GLP toxicology study designs and supporting the safety sections of IND submissions. They provide crucial data on tissue tropism, clearance kinetics, and potential germline transmission risks. Typically, biodistribution assays rely on qualified ddPCR methods that have been rigorously evaluated for sensitivity, specificity, and accuracy across relevant tissue matrices. While full GMP validation is not required for nonclinical biodistribution studies, thorough assay qualification ensures high data integrity and regulatory acceptance.

Vector Shedding Studies

Vector shedding studies are designed to determine whether AAV vector genomes are excreted from treated individuals through biological fluids such as blood, urine, saliva, feces, or semen. These studies are critical for assessing the potential risk of horizontal transmission or environmental exposure following gene therapy administration. Clinical samples are collected at multiple time points post-dosing, typically on days 1, 7, 14, 30, 60, and 90—and analyzed using ddPCR assays targeting AAV-specific sequences. The data usually reveal a transient presence of vector DNA with a rapid decline over time, confirming that recombinant AAV vectors are non-replicating and present minimal risk for secondary transmission.

From a regulatory perspective, shedding data contribute to clinical biosafety evaluations by informing patient counseling, contraception guidance, and environmental release assessments required by regulatory agencies and institutional biosafety committees. These studies rely on qualified ddPCR assays that demonstrate high sensitivity for detecting low copy numbers and strong specificity to distinguish recombinant AAV sequences from naturally occurring wild-type AAV. Such rigor ensures the reliability of shedding assessments in support of clinical trial safety and regulatory compliance.

Lot Release Testing

Lot release testing verifies that each AAV batch meets quality specifications before clinical use. Among critical quality attributes (CQAs), vector genome titer is essential as it directly defines patient dosing. ddPCR quantifies intact vector genomes containing full-length transgene cassettes with ITRs, providing absolute copy numbers per milliliter without standard curves and offering higher accuracy than qPCR.

The full-to-empty capsid ratio is calculated by combining ddPCR genome titers with total capsid counts from analytical ultracentrifugation, TEM, or charge detection mass spectrometry, serving as a key indicator of manufacturing consistency and product quality.

Accurate genome titer measurement is a regulatory requirement for batch release, ensuring proper dosing and therapeutic efficacy. ddPCR assays for lot release must be fully validated under GMP conditions following ICH Q2(R2), assessing accuracy, precision, specificity, linearity, range, and robustness. All supporting electronic data systems must comply with 21 CFR Part 11 to ensure data integrity and traceability.

Stability Testing

Stability programs define the product’s shelf life, storage conditions, and in-use stability by monitoring critical quality attributes (CQAs) over time under controlled conditions. ddPCR is used to quantify vector genome titer at set intervals, typically 0, 1, 3, 6, 9, 12, 18, and 24 months, under both real-time (recommended storage) and accelerated (elevated temperature) conditions. Multiplex or two-dimensional ddPCR assays may be applied to assess genome integrity by targeting both 5′ and 3′ regions of the transgene, enabling detection of partial degradation or fragmentation.

Stability data generated from these studies establish product expiration dates, support storage and shipping recommendations, and substantiate shelf-life claims in regulatory submissions such as INDs and BLAs. Stability-indicating ddPCR assays must be fully validated under GMP, demonstrating high precision (CV ≤ 15%) and accuracy in detecting changes in genome titer or integrity. All testing is conducted within a controlled stability program using qualified equipment, calibrated instruments, and trained personnel in compliance with GMP-standard SOPs.

Conclusions

Droplet digital PCR has established itself as a cornerstone analytical technology for AAV gene therapy development, offering unparalleled quantitative accuracy, robustness, and regulatory acceptance. By enabling precise measurement of transgene expression at the mRNA level and vector genome copies at the DNA level, ddPCR provides direct, biologically relevant readouts of vector potency and quality.

The systematic four-stage development strategy outlined here, from feasibility through optimization, characterization, and implementation, ensures that ddPCR-based potency assays are scientifically sound, technically robust, and fit for their intended regulatory purpose. By embracing a phase-appropriate validation philosophy, development teams can efficiently deploy assays tailored to the risk and requirements of each stage, from early research through commercial manufacturing.

As gene therapy continues its rapid evolution from experimental medicine to mainstream therapeutics, the analytical methods that ensure product quality and patient safety will remain critical. The ddPCR platform, with its unique combination of precision, simplicity, and regulatory credibility, is positioned to play an increasingly central role in bringing these life-changing therapies to patients.

References

  1. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2(R2). Current Step 4 version.
  2. United States Food and Drug Administration. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products. 2011.
  3. United States Food and Drug Administration. Guidance for Industry: Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). 2020.
  4. European Medicines Agency. Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. 2020.
  5. Lock M, et al. Rapid, Simple, and Quantitative Potency Assay for AAV Vectors Based on Transgene Expression. Molecular Therapy – Methods & Clinical Development. 2021;20:918-930.
  6. Rodgers BD, Herring SK, Carias DR, Chen J, Rocha AG. Development and validation of a model gene therapy biodistribution assay for AVGN7 using digital droplet polymerase chain reaction. Mol Ther Methods Clin Dev. 2023;29:494-503. doi: 10.1016/j.omtm.2023.05.007.
  7. Blay E, et al. PCR-based analytics of gene therapies using adeno-associated virus vectors: Considerations for cGMP method development. Molecular Therapy Methods & Clinical Development. 2023;31:101132. doi: 10.1016/j.omtm.2023.101132.
  8. Bustin SA, Benes V, Garson JA, et al. The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clinical Chemistry. 2009;55(4):611-622. doi: 10.1373/clinchem.2008.112797.
  9. BioMarin Pharmaceutical Inc. Blood Biodistribution and Vector Shedding of Valoctocogene Roxaparvovec in People with Severe Hemophilia A: Results from the Phase 3 GENEr8-1 Trial.

 
For additional guidance on phase-appropriate assay selection and regulatory strategy, see:
Marin Bio White Paper: Selecting Bioanalytical Assays for FDA-Approved Clinical Trials and Commercialization

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)